1. 201P Phase II study of taminadenant (A2AR antagonist) + spartalizumab (anti PD-1 antibody) in patients with triple-negative breast cancer (TNBC). (December 2022) Authors: Jerusalem, G.; De Braud, F.G.M.; de Jonge, M.J.A.; Grell, P.; Gonçalves, A.; Tan, T.J.Y.; Greil, R.; Yap, T.A.; Lin, C-C.; Kornbluth, K.A.; Yang, X.; Vong, C.; Choudhury, S.; Mataraza, J.; Lee, L.H.; Otero, J.A.; Garralda, E. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with non-small cell lung cancer (NSCLC). (October 2020) Authors: Lin, C.C.; Joerger, M.; Grell, P.; Chiappori, A.A.; Leal, T.A.; Kasper, S.; Jerusalem, G.; Gonçalves, A.; Wolf, J.; De Braud, F.; de Jonge, M.J.A.; Otero, J.; Chhagan, S.; Cipolletta, D.; Morris, E.; Chowdhury, N.R.; Hurtado, F.K.; Tan, D.S. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗